Altre lingue Alzamend Neuro, Inc.

Azioni

ALZN

US02262M4078

Tempo differito Nasdaq Altri mercati azionari 19:30:00 03/07/2024			Variaz. 5gg	Var. 1 gen.
0,39 ^USD	-1,52%		+1,04%	-56,18%

25/03	Alzamend Neuro, Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 31 gennaio 2024	CI
05/01	Alzamend Neuro, Inc. nomina Milton C. Ault, III come Direttore e Vicepresidente	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel	22/05
Alzamend Neuro Announces Initial Closing of Private Placement	14/05
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million	09/05
Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding	09/05
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program	07/05
Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	25/03
Alzamend Neuro, Inc. announced that it expects to receive $6 million in funding from Ault Lending, LLC	31/01
Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman	05/01
Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	15/12
Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	12/12
Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	11/12
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	11/12
Alzamend Neuro Receives FDA Approval to Proceed With Phase 2A Study of AL001 Depression Treatment Candidate	20/11
Alzamend Neuro Gets FDA Approval for Trial of Depression Treatment	20/11
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	20/11
Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	20/11
Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement	17/11
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement	16/11
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001	13/11
Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001	13/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Alzamend Neuro, Inc.

Azioni

ALZN

US02262M4078

Altre lingue

Filtri